Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

J&J acquisition of Ambrx bolsters cancer ADC portfolio amidst big pharma’s growing investment trend, says GlobalData

Following the news that Johnson & Johnson (J&J) has entered into a definitive agreement to acquire clinical-stage biopharmaceutical company Ambrx Biopharma for $2.0 billion; Israel Stern, MSc,  Oncology & Hematology Analyst at GlobalData, a leading data and analytics company, offers his view: “J&J will have the rights to antibody-drug conjugate (ADC)-focused biotech, which includes anvatabart […]
Read more

AbbVie’s Produodopa holds potential to become first-choice pump for advanced Parkinson’s, says GlobalData

Following the news that  AbbVie has launched Produodopa (foscarbidopa/foslevodopa), to treat severe motor fluctuations in patients with advanced Parkinson’s disease (PD) in the European Union (EU). Christie Wong, Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “AbbVie’s Produodopa is the first-to-market subcutaneous infusion of levodopa. Produodopa uses a VYAFUSER pump […]
Read more

Bluebird second reimbursement deal provides valuable advantage for Lyfgenia in upcoming battle for market share, says GlobalData

Following the news that Massachusetts-based biotechnology company bluebird bio Inc (bluebird bio) has signed a second outcomes-based reimbursement deal with a large commercial payer for its sickle cell disease gene therapy, Lyfgenia (lovotibeglogene autotemcel); Nancy Jaser, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Combined with its first coverage […]
Read more

Biotech funding recovery is on the horizon in 2024, says GlobalData

Over 2022 and 2023, biotech funding saw significant change, with a marked downturn in investment. Hoverer, the post-pandemic slump is expected to end with the market heading to recovery in 2024, finds GlobalData, a leading data and analytics company. A recent GlobalData’s survey “The State of the Biopharmaceutical Industry 2024” found that overall, more than […]
Read more

Ractigen’s RAG-01 becomes second saRNA drug globally to advance to clinical stage, says GlobalData

Ractigen Therapeutics, headquartered in China, submitted a clinical trial application for RAG-01 in Australia. This application paves the way for Phase I trial of RAG-01 in patients with non-muscle-invasive bladder cancer (NMIBC) who have not responded to Bacillus Calmette-Guérin (BCG) therapy, making it globally the second saRNA drug to advance into the clinical stage, says […]
Read more

Geopolitical conflicts, inflation, and drug pricing pressures will be top challenges for pharma industry growth in 2024, finds GlobalData

Lingering inflation, geopolitical tensions, and conflicts, as well as continuous pressures to cut drug prices, will be the top challenges for the pharmaceutical industry in 2024, finds GlobalData, a leading data and analytics company. GlobalData’s recent survey “The State of the Biopharmaceutical Industry 2024” found that drug pricing and reimbursement constraints elicited the strongest responses […]
Read more

GLP-1R agonist withdrawal effect on weight loss and cardiovascular risks remains unmet need, says GlobalData

Eli Lilly recently published the results of a Phase III trial investigating the maintenance of Zepbound’s weight loss effects in overweight and obesity patients. Zepbound is Eli Lilly’s new glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) dual agonist, approved by the FDA in November 2023, showing great promise compared to the other GLP-1R agonists on the market. […]
Read more

Inflammatory bowel disease market risks contraction, says GlobalData

In recent years, the increase in inflammatory bowel disease (IBD) biologic treatments has been a major driving force in the growth of this market. In 2007, AbbVie’s Humira received approval from the FDA to treat moderate-severe Crohn’s disease (CD). Since then, the IBD market has seen the entry of seven biologics. With more biologics anticipated […]
Read more

Female contraceptives market across 7MM to see only slight growth over next 10 years, forecasts GlobalData

The female contraceptives market across the seven major markets (7MM*) is forecast to slightly increase at a compound annual growth rate (CAGR) of 0.5% from $7.8 billion in 2022 to $8.2 billion in 2032, according to GlobalData, a leading data and analytics company. GlobalData’s latest report “Female Contraceptives in Major Markets, Disease Management, Epidemiology, Pipeline […]
Read more

Positive Rezzayo data marks milestone in candidemia and invasive candidiasis treatment, says GlobalData

Melinta Therapeutics and Cidara Therapeutics released extensive data from two global clinical trials on their candidemia and invasive candidiasis drug Rezzayo (rezafungin acetate). The findings affirm the safety and efficacy of Rezzayo, a novel echinocandin antifungal administered through weekly intravenous (IV) infusion. This reinforces its market position, emphasizing its efficacy and safety in addressing fungal […]
Read more

New CAR-T therapies in South Korea to face stringent regulatory oversight, says GlobalData

South Korea has issued guidelines to monitor the side effects of the two approved CAR-T therapies – Kymriah (tisagenlecleucel) from Novartis and Carvykti (ciltacabtagene autoleucel) from Janssen. This will ensure a comprehensive database of adverse events including malignancies, if any in the local population, thereby ensuring patient safety in the country. However, regulatory focus on […]
Read more
1 … 26 27 28 29 30 … 110